MA-ROSLINCT
RoslinCT, a leading cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), is pleased to announce the appointment of Professor Sir Peter Mathieson MB BS (Hons), PhD, FRCP, FRCPE, FMedSci, FRSE, FRSA and Alexander Vos as new Non-Executive Directors.
Professor Sir Peter Mathieson brings an exceptional wealth of experience in higher education, medical research, and organisational leadership. Currently serving as the Principal of the University of Edinburgh since 2018, Sir Peter also holds Honorary Professorships in Medicine at the Universities of Edinburgh, Hong Kong, and Bristol. His illustrious career includes notable roles such as President of the University of Hong Kong (2014-18) and Dean of the Faculty of Medicine & Dentistry at the University of Bristol (2008-14). Sir Peter was knighted in the 2023 New Year Honours for his services to higher education, reflecting his significant contributions to the field. Additionally, Sir Peter has held numerous non-executive and trustee roles, including positions with the Renal Association, Council for the Advancement and Support of Education (CASE), Scottish Funding Council, and Newbattle Abbey College Trust. His career highlights also include tenure as an honorary consultant nephrologist with a clinical interest in autoimmune diseases and renal transplantation. He has led a significant research group in Bristol and contributed extensively to medical education and clinical research, particularly in Africa. His publication record includes 327 works, covering clinical trials, laboratory research, and societal matters, and he has been a driving force in academic careers both in the UK and internationally.
Alexander Vos is a biotech leader with 30 years of experience, specializing in biopharmaceuticals and cell & gene therapy. He started at McKinsey & Co. and held executive roles at Genzyme Therapeutics Europe. He was CEO of MediService AG, PAION AG's Deputy-CEO and COO, and led PharmaCell BV to a successful sale to Lonza. Vos also served as CEO of VarmX and VectorY, setting strategy and raising significant funds for these companies. Currently, he sits on several biotech boards and is a Venture Partner at BioGeneration Ventures. He holds an MS in Pharmacy and Pharmacology and an MBA from Stanford University. Alexander Vos's proven leadership in advancing innovative therapies and achieving successful exits for investors will be invaluable to RoslinCT. His skills in biotech strategy development, operations, and M&A will complement the existing strengths of the board.
"We are excited to welcome both Professor Sir Peter Mathieson and Alexander Vos to our Board," said Geoffrey Hamilton Fairley, Executive Chairman of the RoslinCT Group. "Sir Peter's extensive experience in academic leadership and his proven track record in advancing medical research and education, combined with Alexander's strategic insight and wealth of experience in biotech and cell and gene therapy, align perfectly with RoslinCT's mission. Their combined expertise will be instrumental as we continue to develop and manufacture cutting-edge cell and gene therapies."
"I am honoured to join RoslinCT at such an exciting time for the company and the field of cell and gene therapy," said Sir Peter Mathieson. "I look forward to contributing to RoslinCT's innovative efforts to bring life-saving therapies to patients worldwide."
Alexander Vos added, "I am excited to be part of RoslinCT's journey and to support its mission to advance cell and gene therapies. The company is at the forefront of groundbreaking science, and I am eager to contribute to its continued success."
About RoslinCT
RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the ground-breaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones. These include being among one of the first in the world to produce clinical-grade human pluripotent stem cells. In collaboration with the partners, RoslinCT also developed the first CRISPR-edited cell therapy product for a major inherited disorder, taking it from early development to commercialisation.
Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation.
With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialisation and deliver life-saving Cell and Gene Therapies worldwide. RoslinCT is a GHO Capital portfolio company. Discover more about our services at www.roslinct.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625300790/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OMRON Releases the “Medium-Term Roadmap SF 2nd Stage”8.11.2025 07:00:00 CET | Press release
OMRON (TOKYO: 6645) has announced its “Medium-Term Roadmap Shaping the Future 2nd Stage (“SF 2nd Stage”),” covering from FY2026 to FY2030, on November 7, 2025 (JST). This Roadmap presents the Group’s vision and growth strategies through 2030, which are disclosed on our corporate website. Overview of the “Medium-Term Roadmap SF 2nd Stage” Since April 2024, OMRON has been implementing a Structural Reform Program “NEXT 2025” aimed at rebuilding our foundation for profitability and growth. With the completion of this Program in September 2025, we have shifted into a growth phase and formulated a new Roadmap looking ahead to 2030. This Roadmap identifies Business Portfolio Restructuring as a core strategy. We have defined Thirteen Focus Businesses to drive the Group’s future growth. By accelerating our selection and concentration efforts, we aim to build a “distinctive” business portfolio that maximizes overall Group growth. Furthermore, to maximize the growth potential of our Focus Busines
26th UN Tourism General Assembly kicks off in Riyadh7.11.2025 22:13:00 CET | Press release
UN Tourism marks 50 years of global cooperation as leaders from across the industry gather to shape the future of tourism. His Excellency Ahmed Al Khateeb, Minister of Tourism – “The Kingdom will play an integral part in ensuring one of the world’s most powerful generators of jobs and GDP grows in harmony with the Sustainable Development Goals.” UN Tourism Secretary-General ZurabPololikashvili – “The UN Tourism General Assembly brings together tourism leaders from across the world to set the agenda and build a more innovative and inclusive sector. From Riyadh, we will set the agenda for tourism for the years ahead.” The 26th session of the UN Tourism General Assembly opened today in Riyadh, marking a historic first for the Gulf Cooperation Council (GCC) region and the largest Assembly since UN Tourism was founded 50 years ago. Around 160 delegations from member states including ministers, senior officials, and leaders from across industry and civil society are coming together to celebr
Xsolla Partners With Deloitte Turkiye and Lorien Accelerator as Category Sponsor for Gaming Awards at Fast 50 Türkiye 2025 Program7.11.2025 19:11:00 CET | Press release
Celebrating Turkey’s Gaming Industry with High-Impact Sponsorship and Industry Panel Xsolla, a leading global video game commerce company that helps developers launch, grow, and monetize their games, is proud to announce its sponsorship of the Gaming Awards segment at the Deloitte Technology Fast 50 Türkiye 2025 Program, organized in collaboration with Lorien Accelerator. The event will take place on December 10, 2025, and will recognize Turkey’s top high-growth companies across various industries, with a special focus on the dynamic gaming sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107671030/en/ Graphic: Xsolla As the Gaming Awards category sponsor, Xsolla will receive significant brand exposure through prominent logo placements across all event materials, including digital platforms, official event signage, and other promotional materials. In addition to this visibility, Xsolla’s participation includes an ex
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy7.11.2025 17:00:00 CET | Press release
− Phase 1b, Open-Label Study Follow Up Shows Stable Kidney Function (eGFR) in Patients Treated with Investigational Mezagitamab Through Week 96 – 18 Months After Last Dose1− Rapid Reductions in Proteinuria and Serum Gd-IgA1 Levels Were Sustained Through Week 961− No Serious Adverse Events or Opportunistic Infections Were Observed Through Week 961− Takeda Initiated Pivotal Phase 3 Clinical Trials Evaluating Mezagitamab in Primary IgA Nephropathy and Immune Thrombocytopenia with Patient Enrollment Ongoing Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin A (IgA) nephropathy. Data from the study showed that kidney function (eGFR) remained stable in patients with IgA nephropathy through Week 96 – up to 18 months after the last mezagitamab dose.1 The results were presented at the American Society o
Oremus Corporate Services Expands into Europe with Launch in Finland7.11.2025 16:23:00 CET | Press release
CEO, Lalit Ananth Chawla, to Attend Slush 2025 in Helsinki Oremus Corporate Services Private Limited, a multinational Finance and Accounting Advisory firm having its offices in the USA, India and the UK, has announced the extension of its services to Finland, marking the company’s foray into the European market. With over two decades of expertise in accounting, payroll, tax compliance, and advisory services, Oremus has earned trust as a technology-driven finance partner serving clients across geographies. Oremus is an ISAE 3402, ISO 27001, GDPR & DPDP Compliant Company, adhering to International Quality and Security Standards. “Finland isn’t just a new market for us — it’s the gateway to meaningful, growth-driven partnerships across Europe”. said Lalit Ananth Chawla, CEO of Oremus. Having established a strong reputation for delivering reliable Accounting and Advisory solutions to scale-ups and growing businesses, we seek to collaborate with like-minded firms and investors to build a tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom